New drug cocktail shows promise for Tough-to-Treat breast cancer
NCT ID NCT02057133
First seen Jan 31, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This early-phase study tested the safety of a new drug called abemaciclib when given with other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) for people whose breast cancer has spread to other parts of the body. About 198 participants with either hormone receptor-positive or HER2-positive breast cancer took part. The main goal was to see how many people had side effects from the drug combinations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University College of Phys & Surgeons
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Highlands Oncology Group - Duplicate 2
Rogers, Arkansas, 72758, United States
-
Mayo Clinic
Rochester, Minnesota, 55905-0002, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Peggy and Charles Stephenson Oklahoma Cancer Center
Nashville, Tennessee, 37203, United States
-
Providence Cancer Center Oncology Hematology Care
Portland, Oregon, 97213, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229-3307, United States
-
Tennessee Oncology PLLC
Nashville, Tennessee, 37203, United States
-
Univ of Pittsburgh Cancer Inst. (UPCI)
Pittsburgh, Pennsylvania, 15213, United States
-
University of California - San Diego
La Jolla, California, 92037-0845, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-6307, United States
Conditions
Explore the condition pages connected to this study.